PageOverview.com
PageOverview.comAll website entries443433433343330433302
Comprehensive Hemlibra.com website statistics analysis:
Site description: 2460 Learn about HEMLIBRA® (emicizumab-kxwh), a hemophilia A treatment now approved for people with hemophilia A with factor VIII inhibitors. See BOXED WARNING. What is HEMLIBRA? HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A with factor VIII inhibitors. What is the most important information I should know about HEMLIBRA? HEMLIBRA increases the potential for your blood to clot. Discontinue prophylactic use of bypassing agents the day before starting HEMLIBRA prophylaxis. Carefully follow your healthcare provider’s instructions regarding when to use an on-demand bypassing agent, and the dose and schedule you should use. HEMLIBRA may cause the following serious side effects when used with aPCC (FEIBA®), including: Thrombotic microangiopathy (TMA). This is a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs. Get medical help right away if you have any of the signs and symptoms of TMA during or after treatment with HEMLIBRA. Blood clots (thrombotic events). Blood clots may form in blood vessels in your arm, leg, lung or head. Get medical help right away if you have any of the signs or symptoms of blood clots during or after treatment with HEMLIBRA. If aPCC (FEIBA®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (FEIBA®) total. How should I use Hemlibra? See the detailed “Instructions for Use” that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes. HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and may cause a false reading. Talk to your healthcare provider about how this may affect your care. What are the other possible side effects of HEMLIBRA? The most common side effects of HEMLIBRA include: redness, tenderness, warmth, or itching at the site of injection; headache; and joint pain. These are not all of the possible side effects of HEMLIBRA. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. Please see the HEMLIBRA full Prescribing Information and Medication Guide for more important safety information including Serious Side Effects.
Website title: Hemophilia A Treatment | HEMLIBRA® (emicizumab-kxwh)
Website Overview: The server, which itself is located in San Jose; United States, has an IP address 52.52.240.22. Overall there are 3 off-site links on the homepage of the website. Expiration of hemlibra.com will occur on June 3rd in 2019. Alexa Global rank for hemlibra.com is 765311. Domain was probably registered on June 3rd in 2015. This domain's WHOIS records was updated on August 31st in 2017. The past 3 months resulted in Alexa position shift by -199703 for hemlibra.com.
Known Profiles
Google Plus Account:Not specified at this time
AddThis User:Not specified at this time
Google Analytics:Not specified at this time
Adsense ID:Not specified at this time
Have any insights?
Index in-depth overview
Server region:San Jose; United States
Site IP address:52.52.240.22
Number of top offsite links
Site Whois details
Associated person phone number:
  1. +49.6841.6984-200
Expected expiration:June 3rd in 2019
Creation date:June 3rd in 2015
Unedited Whois text:

Domain Name: HEMLIBRA.COM Registry Domain ID: 1935058320_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.1api.net Registrar URL: http://www.1api.net Updated Date: 2017-08-31T11:46:12Z Creation Date: 2015-06-03T09:37:35Z Registry Expiry Date: 2019-06-03T09:37:35Z Registrar: 1 API GmbH Registrar IANA ID: 1387 Registrar Abuse Contact Email: Email profile not revealed Registrar Abuse Contact Phone: +49.6841.6984-200 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: DNADNS2E.GENE.COM Name Server: DNADNS3E.GENE.COM Name Server: DNADNS4E.GENE.COM DNSSEC: unsigned URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/ >>> Last update of whois database: 2018-02-05T12:12:56Z <<< For more information on Whois status codes, please visit https://icann.org/epp NOTICE: The expiration date displayed in this record is the date the registrar's sponsorship of the domain name registration in the registry is currently set to expire. This date does not necessarily reflect the expiration date of the domain name registrant's agreement with the sponsoring registrar. Users may consult the sponsoring registrar's Whois database to view the registrar's reported date of expiration for this registration. TERMS OF USE: You are not authorized to access or query our Whois database through the use of electronic processes that are high-volume and automated except as reasonably necessary to register domain names or modify existing registrations; the Data in VeriSign Global Registry Services' ("VeriSign") Whois database is provided by VeriSign for information purposes only, and to assist persons in obtaining information about or related to a domain name registration record. VeriSign does not guarantee its accuracy. By submitting a Whois query, you agree to abide by the following terms of use: You agree that you may use this Data only for lawful purposes and that under no circumstances will you use this Data to: (1) allow, enable, or otherwise support the transmission of mass unsolicited, commercial advertising or solicitations via e-mail, telephone, or facsimile; or (2) enable high volume, automated, electronic processes that apply to VeriSign (or its computer systems). The compilation, repackaging, dissemination or other use of this Data is expressly prohibited without the prior written consent of VeriSign. You agree not to use electronic processes that are automated and high-volume to access or query the Whois database except as reasonably necessary to register domain names or modify existing registrations. VeriSign reserves the right to restrict your access to the Whois database in its sole discretion to ensure operational stability. VeriSign may restrict or terminate your access to the Whois database for failure to abide by these terms of use. VeriSign reserves the right to modify these terms at any time. The Registry database contains ONLY .COM, .NET, .EDU domains and Registrars.

Renew date:August 31st in 2017
How frequently employedTag keywords tableUse denseness
No data yetNo data yetNo data yet
Known Alexa ranks data
Rank in target country:No data yet
Alexa stats updated on:June 9th in 2018
Global Alexa rank over the past year
Capacity rating:No data yet
Delta of the rating:-199703
30 day statistics overview
Global ranking:765311
Webpage target country:No data yet
Complementary links
Not specified at this time
Server header response:
Last-Modified: Tue, 13 Feb 2018 05:16:34 GMT ServerID: web02 Accept-Ranges: bytes Date: Tue, 13 Feb 2018 16:39:28 GMT HTTP/1.1 200 OK ETag: "e27c-56511192993a5" Content-Type: text/html; charset=UTF-8 Connection: keep-alive Content-Length: 57980 Server: Apache
How safe is the website
Google Safety Rank:No data yet
WOT Safety Evaluation:No data yet
Child Safety by WOT:No data yet
Similar statistics
0.0226 // 2024-05-10 00:01:05
All Rights reserved 2018 © PageOverview.com